[1]孙 茜,柴明思,齐秀芳.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢阻肺的疗效及对CRP、SaO2、pH水平影响[J].医学信息,2023,36(10):150-153.[doi:10.3969/j.issn.1006-1959.2023.10.033]
　SUN Qian,CHAI Ming-si,QI Xiu-fang.Efficacy of Budesonide Formoterol Combined with Tiotropium Bromide Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on CRP, SaO2 and pH Levels[J].Journal of Medical Information,2023,36(10):150-153.[doi:10.3969/j.issn.1006-1959.2023.10.033]
点击复制

布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢阻肺的疗效及对CRP、SaO2、pH水平影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年10期
页码:
150-153
栏目:
论著
出版日期:
2023-05-15

文章信息/Info

Title:
Efficacy of Budesonide Formoterol Combined with Tiotropium Bromide Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on CRP, SaO2 and pH Levels
文章编号:
1006-1959（2023）10-0150-04
作者:
孙 茜; 柴明思; 齐秀芳
（佳木斯市中心医院呼吸科，黑龙江 佳木斯 154002）
Author(s):
SUN Qian; CHAI Ming-si; QI Xiu-fang
(Department of Respiratory,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
慢阻肺; 布地奈德福莫特罗; 噻托溴铵; C-反应蛋白; 血氧饱和度
Keywords:
Chronic obstructive pulmonary disease; Budesonide formoterol; Tiotropium bromide; C-reactive protein; Blood oxygen saturation
分类号:
R563.9
DOI:
10.3969/j.issn.1006-1959.2023.10.033
文献标志码:
A
摘要:
目的 探究布地奈德福莫特罗（BD/FM）联合噻托溴铵（TB）吸入剂治疗慢阻肺（COPD）的临床疗效及对患者C反应蛋白（CRP）、血氧饱和度（SaO2）、pH水平的影响。方法 选取2019年3月-2022年3月佳木斯市中心医院收治的80例COPD患者，采用随机数字表法分为对照组（40例）和观察组（40例）。对照组给予BD/FM吸入治疗，观察组应用BD/FM联合TB吸入剂治疗，比较两组临床疗效、血气分析指标[血氧饱和度（SaO2）、动脉血二氧化碳分压（PaCO2）、pH值]、肺通气功能[用力肺活量（FVC）、1 s用力呼气容积（FEV1）、1 s率（FEV1/FVC）]、生化指标[C反应蛋白（CRP）、白细胞介素-6（IL-6）]、不良反应。结果 观察组治疗有效率高于对照组（P＜0.05）；观察组治疗后SaO2、pH值高于对照组，PaCO2低于对照组（P＜0.05）；观察组治疗后FVC、FEV1、FEV1/FVC高于对照组，CRP、IL-6低于对照组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 BD/FM联合TB吸入治疗COPD疗效肯定，可有效改善患者血氧状态及肺通气功能，提高SaO2、PH指标，下调CRP等炎性表达，且不增加不良反应。
Abstract:
Objective To investigate the clinical efficacy of budesonide formoterol (BD/FM) combined with tiotropium bromide (TB) inhalation in the treatment of chronic obstructive pulmonary disease (COPD) and its effect on C-reactive protein (CRP), oxygen saturation (SaO2) and pH level.Methods A total of 80 patients with COPD admitted to Jiamusi Central Hospital from March 2019 to March 2022 were selected and divided into control group (40 patients) and observation group (40 patients) by random number table method. The control group was treated with BD/FM inhalation, and the observation group was treated with BD/FM combined with TB inhalation. The clinical efficacy, blood gas analysis indexes [oxygen saturation (SaO2), arterial carbon dioxide partial pressure (PaCO2), pH value], pulmonary ventilation function [forced vital capacity (FVC), forced expiratory volume in one second (FEV1), forced vital capacity rate of one second (FEV1/FVC)], biochemical indexes [C-reactive protein (CRP), interleukin-6 (IL-6)] and adverse reactions were compared between the two groups.Results The effective rate of treatment in the observation group was higher than that in the control group (P<0.05). After treatment, SaO2 and pH in the observation group were higher than those in the control group, and PaCO2 was lower than that in the control group (P<0.05). FVC, FEV1 and FEV1/FVC in the observation group were higher than those in the control group, and CRP and IL-6 were lower than those in the control group after treatment (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05).Conclusion BD/FM combined with TB inhalation is effective in the treatment of COPD, which can effectively improve the blood oxygen status and pulmonary ventilation function of patients, improve the indexes of SaO2 and PH, and down-regulate the inflammatory expression of CRP without increasing adverse reactions.

参考文献/References:

[1]邢振川,郭华征,高芸菲.硫酸特布他林联合布地奈德混悬液雾化吸入治疗慢阻肺急性加重期的疗效及对血清PCT、IL-6、IFN-γ水平变化的影响[J].解放军预防医学杂志,2019,37(10):20-21.[2]刘苔,黄海霞,杜卫祺,等.噻托溴铵辅助治疗对COPD急性加重期患者JAK/STAT通路蛋白及血气指标的影响[J].中南医学科学杂志,2021,49(4):464-467.[3]梁起芳,马海滨,贺丽菁,等.噻托溴铵联合布地奈德福莫特罗对慢性阻塞性肺疾病稳定期患者治疗效果观察[J].中国药物与临床,2020,20(16):2736-2737.[4]Keating GM.Budesonide/formoterol Easyhaler: a guide to its use in asthma and chronic obstructive pulmonary disease[J].Drugs & Therapy Perspectives,2017,33(3):95-101.[5]石慧,云春梅,魏慧,等.噻托溴铵联合布地奈德福莫特罗治疗哮喘-慢阻肺重叠综合征临床观察[J].中国药师,2020,23(5):901-904.[6]刘斌,冉献贵,邢青峰,等.噻托溴铵联合信必可都保治疗对慢阻肺患者肺功能和运动耐量及不良反应的影响[J].河北医学,2019,25(7):1108-1112.[7]贾美莹,王银叶.噻托溴铵吸入剂治疗稳定期慢性阻塞性肺疾病疗效观察[J].海南医学,2020,31(5):589-592.[8]中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志,2021,44(3):170-205.[9]Yi G,Liang M,Li M,et al.A large lung gene expression study identifying IL1B as a novel player in airway inflammation in COPD airway epithelial cells[J].Inflammation Research,2018,67(6):539-551.[10]秦茵茵,高国英,谢晓鸿,等.噻托溴铵对慢性阻塞性肺疾病患者呼吸中枢驱动影响的临床研究[J].中国实用内科杂志,2018,38(11):1086-1089.[11]刘颖,薄晓霞,张亚娟.布地奈德福莫特罗、噻托溴铵、家庭无创正压通气对慢性阻塞性肺疾病患者影响的研究[J].临床肺科杂志,2018,23(8):1394-1397.[12]李方方,张高峰.噻托溴铵+信必可都保治疗慢阻肺的有效性及对患者运动耐力的影响[J].贵州医药,2021,45(9):1396-1397.[13]吴丽燕.布地奈德福莫特罗吸入剂和噻托溴铵吸入治疗老年慢性阻塞性肺疾病的临床研究[J].中国药物与临床,2019,19(18):3146-3148.[14]黄骁燕,余维巍,刘建.噻托溴铵喷雾剂对中重度稳定期慢性阻塞性肺疾病患者睡眠质量和肺功能的影响[J].中国医师进修杂志,2018,41(3):197-200.[15]庄英鸿,尚东,巫瑞.噻托溴铵联合布地奈德福莫特罗吸入剂治疗稳定期慢性阻塞性肺疾病的临床疗效研究[J].药物评价研究,2017,40(11):1626-1630.[16]夏文娟,王学中.布地奈德福莫特罗联合噻托溴铵对慢性阻塞性肺疾病急性加重期的临床疗效[J].安徽医学,2017,38(12):1572-1574.[17]赵洪达,许群,刘澄英.噻托溴铵孟鲁司特钠与布地奈德福莫特罗吸入剂联合治疗对老年慢性阻塞性肺疾病患者临床疗效及血清降钙素原和高敏C反应蛋白的影响[J].山西医药杂志,2017,46(21):2638-2640.[18]韩娟,颜浩,徐淑晖,等.噻托溴铵联合布地奈德福莫特罗对慢性阻塞性肺疾病的疗效及对TGF-β、TIMP-1、IL-6水平的影响[J].现代生物医学进展,2018,18(13):2531-2534,2544.[19]许柳柳,朱洁晨,卞宏,等.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢阻肺疗效及对CRP、SaO2、pH水平影响[J].现代生物医学进展,2020,20(22):4369-4372.[20]余霓雯,王玉婷.噻托溴铵联合布地奈德福莫特罗对慢性阻塞性肺疾病的疗效及血清TGF-β、MMP-9、TIMP-1水平的影响[J].东南国防医药,2017,19(2):183-186.[21]崔丽平,陈希胜,李旭.布地奈德粉吸入剂联合噻托溴铵粉雾剂治疗哮喘-慢阻肺重叠综合征的临床疗效[J].实用心脑肺血管病杂志,2017,25(3):100-103.[22]赵瑞芬,李霞,杨亚萍,等.噻托溴铵联合布地奈德/福莫特罗对慢性阻塞性肺疾病患者血管内皮功能及T淋巴细胞亚群的影响[J].心肺血管病杂志,2018,37(2):98-102.

相似文献/References:

[1]黄朝宗.无创呼吸机对慢性阻塞性肺疾病急性加重患者治疗效果的影响[J].医学信息,2018,31(01):112.[doi:10.3969/j.issn.1006-1959.2018.01.042]
　HUANG Chao-zong.Effect of Noninvasive Ventilator on the Treatment of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(10):112.[doi:10.3969/j.issn.1006-1959.2018.01.042]
[2]温 蕾.复方异丙托溴铵常温雾化与加温雾化治疗 慢阻肺的护理效果分析[J].医学信息,2018,31(06):170.[doi:10.3969/j.issn.1006-1959.2018.06.061]
　WEN Lei.Analysis of Nursing Effect of Compound Ipratropium Bromide Nebulization at Room Temperature and Heating Atomization in Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(10):170.[doi:10.3969/j.issn.1006-1959.2018.06.061]
[3]王春艳,平玉卓,赵秀芹,等.协同护理干预对慢阻肺患者预后及自我护理能力的影响观察[J].医学信息,2018,31(13):181.[doi:10.3969/j.issn.1006-1959.2018.13.057]
　WANG Chun-yan,PING Yu-zhuo,ZHAO Xiu-qin,et al.Effect of Cooperative Nursing Intervention on Prognosis and Self-care Ability of Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(10):181.[doi:10.3969/j.issn.1006-1959.2018.13.057]
[4]鲁 婧,杜 君.肺心病左室舒张功能障碍发病机制的研究进展[J].医学信息,2019,32(04):54.[doi:10.3969/j.issn.1006-1959.2019.04.019]
　LU Jing,DU Jun.Advances in the Pathogenesis of Left Ventricular Diastolic Dysfunction in Pulmonary Heart Disease[J].Journal of Medical Information,2019,32(10):54.[doi:10.3969/j.issn.1006-1959.2019.04.019]
[5]周 笳,董丽霞.阿替普酶联合华法林治疗慢阻肺合并肺栓塞的有效性分析[J].医学信息,2019,32(05):146.[doi:10.3969/j.issn.1006-1959.2019.05.046]
　ZHOU Jia,DONG Li-xia.Efficacy Analysis of Alteplase Combined with Warfarin in the Treatment of Chronic Obstructive Pulmonary Disease with Pulmonary Embolism[J].Journal of Medical Information,2019,32(10):146.[doi:10.3969/j.issn.1006-1959.2019.05.046]
[6]刘伟娜.CD64感染指数、BODE指数与降钙素原在慢阻肺患者中的水平变化[J].医学信息,2019,32(06):125.[doi:10.3969/j.issn.1006-1959.2019.06.039]
　LIU Wei-na.Changes of CD64 Infection Index,BODE Index and Procalcitonin Levels in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2019,32(10):125.[doi:10.3969/j.issn.1006-1959.2019.06.039]
[7]钟红燕.盐酸氨溴索治疗慢阻肺合并肺部感染的临床效果[J].医学信息,2019,32(12):154.[doi:10.3969/j.issn.1006-1959.2019.12.051]
　ZHONG Hong-yan.Clinical Effect of Ambroxol Hydrochloride in the Treatment of Chronic Obstructive Pulmonary Disease with Pulmonary Infection[J].Journal of Medical Information,2019,32(10):154.[doi:10.3969/j.issn.1006-1959.2019.12.051]
[8]郑 新,张 颖.慢阻肺患者PSQI评分与NLR、PLR、CRP水平及急性加重频率的相关性[J].医学信息,2020,33(12):103.[doi:10.3969/j.issn.1006-1959.2020.12.031]
　ZHENG Xin,ZHANG Ying.Correlation of PSQI Score with NLR,PLR,CRP Level and Frequency of Acute Exacerbation in COPD Patients[J].Journal of Medical Information,2020,33(10):103.[doi:10.3969/j.issn.1006-1959.2020.12.031]
[9]田 芳.叙事护理对COPD患者负性情绪和呼吸症状群管理的效果[J].医学信息,2020,33(19):178.[doi:10.3969/j.issn.1006-1959.2020.19.058]
　TIAN Fang.The Effect of Narrative Nursing on the Management of Negative Emotion and Respiratory Symptoms in COPD Patients[J].Journal of Medical Information,2020,33(10):178.[doi:10.3969/j.issn.1006-1959.2020.19.058]
[10]李 婷.呼吸功能锻炼联合饮食护理干预对COPD生活质量的影响[J].医学信息,2021,34(01):188.[doi:10.3969/j.issn.1006-1959.2021.01.053]
　LI Ting.Effect of Respiratory Function Exercise Combined with Diet and Nursing Intervention on Life Quality of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2021,34(10):188.[doi:10.3969/j.issn.1006-1959.2021.01.053]
[11]王丽丽,石景瑜,张 敏.布地奈德福莫特罗联合噻托溴铵治疗慢阻肺稳定期的临床疗效及药理学分析[J].医学信息,2022,35(23):136.[doi:10.3969/j.issn.1006-1959.2022.23.028]
　WANG Li-li,SHI Jing-yu,ZHANG Min.Clinical Efficacy and Pharmacological Analysis of Budesonide Formoterol Combined with Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(10):136.[doi:10.3969/j.issn.1006-1959.2022.23.028]
[12]王浩凌,李冬琼,吴 旭,等.布地奈德联合噻托溴铵治疗慢阻肺的效果及对CRP、SaO2、pH水平的影响[J].医学信息,2023,36(06):143.[doi:10.3969/j.issn.1006-1959.2023.06.031]
　WANG Hao-ling,LI Dong-qiong,WU Xu,et al.Effect of Budesonide Combined with Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on CRP,SaO2 and pH Levels[J].Journal of Medical Information,2023,36(10):143.[doi:10.3969/j.issn.1006-1959.2023.06.031]

更新日期/Last Update: 1900-01-01